Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma

ABSTRACT: Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma

PROVIDER: PRJNA418192 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6286710.fastq.gz	Fastqsanger.gz
	SRR6286711.fastq.gz	Fastqsanger.gz
	SRR6286712.fastq.gz	Fastqsanger.gz
	SRR6286713.fastq.gz	Fastqsanger.gz
	SRR6286704.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Gene expression signatures associated with Perineural Invasion in pancreatic ductal adenocarcinoma

Project description:Perineural invasion (PNI) is a prominent characteristic of pancreatic ductal adenocarcinoma (PDAC) and indicates poor prognosis. The invasion of the surrounding nerves by pancreatic cancer cells not only provides route for metastasis but also contributes to neural remodeling and changes in the neuronal milieu that can profoundly influenced the microenvironment of pancreatic cancer. To investigate the downstream molecules associated with PNI, the experiment analyzed mRNA expression of 50 pairs of pancreatic ductal adenocarcinoma tissue and paired adjacent non-tumor tissue, among which 28 pairs of cases diagnosed with PNI by experienced pathologist. Results provide new insight into molecular basis for the influence of PNI on the microenvironment of pancreatic cancer.

2017-08-04 | GSE102238 | GEO

Pancreatic ductal adenocarcinoma

Project description:Pancreatic ductal adenocarcinoma

| PRJNA432344 | ENA

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma

Project description:Pancreatic cancer is characterized by nearly universal activating mutations in KRAS. Among other somatic mutations, TP53 is mutated in more than 75% of human pancreatic tumors. Genetically engineered mice have proven instrumental in studies of the contribution of individual genes to carcinogenesis. Oncogenic Kras mutations occur early during pancreatic carcinogenesis and are considered an initiating event. In contrast, mutations in p53 occur later during tumor progression. In our model, we recapitulated the order of mutations of the human disease, with p53 mutation following expression of oncogenic Kras. Further, using an inducible and reversible expression allele for mutant p53, we inactivated its expression at different stages of carcinogenesis. Notably, the function of mutant p53 changes at different stages of carcinogenesis. Our work establishes a requirement for mutant p53 for the formation and maintenance of pancreatic cancer precursor lesions. In tumors, mutant p53 becomes dispensable for growth. However, it maintains the altered metabolism that characterizes pancreatic cancer and mediates its malignant potential. Further, mutant p53 promotes epithelial-mesenchymal transition (EMT) and cancer cell invasion. This work generates new mouse models that mimic human pancreatic cancer and expands our understanding of the role of p53 mutation, common in the majority of human malignancies.

2018-09-05 | GSE106853 | GEO

Gene expression in pancreatic ductal adenocarcinoma

Project description:To further develop our understanding of the gene expression signature of pancreatic ductal adenocarcinoma Gene expression signatures in macrodissected resected pancreatic ductal adenocarcinoma specimens

2014-03-14 | E-GEOD-55643 | biostudies-arrayexpress

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.

| S-EPMC5821189 | biostudies-literature

Expression profiling of pancreatic adenocarcinoma and ductal adenocarcinoma cell lines.

Project description:We characterized baseline gene expression profiles for eleven human pancreatic adenocarcinoma and ductal adenocarcinoma cell lines.

2018-11-22 | GSE122818 | GEO

Pancreatic ductal adenocarcinoma

Project description:We sought to determine whether certain miRNAs could serve as a biomarker for the prognosis of pancreatic ductal adenocarcinoma (PDAC) and uncover the uncharacterized miRNAs function in the pancreatic carcinogenesis

2019-10-01 | GSE109918 | GEO

Development of lncRNA and Mrna expression signatures for pancreatic ductal adenocarcinoma

Project description:To further development of our lncRNA and mRNA expression approach to pancreatic ductal adenocarcinoma(PDAC), we have employed lncRNA and mRNA microarray expression profiling as a discovery platform to identify lncRNA and mRNA expression in pancreatic ductal adenocarcinoma.Human pancreatic ductal adenocarcinoma tissues and normal pancreatic tissues from PDAC donors and other duodenum diseases donors. analyze mRNA and lncRNA expression in pancreatic ductal adenocarcinoma (PDAC) by microarray platform

2014-11-18 | E-GEOD-57144 | biostudies-arrayexpress

MS-based proteomic analysis of pancreatic ductal adenocarcinoma

Project description:Disease-related quantitative protein expressions of pancreatic ductal adenocarcinoma were acquired by high accuracy mass spectrometry following liquid chromatography peptide separation.

2022-03-21 | PXD032681 | JPOST Repository

Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma

Project description:Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma

| PRJNA776848 | ENA